AstraZeneca's Global First-in-Class Tri-specific Antibody AZD9793 Granted IND Approval in China for GPC3-Positive Solid Tumors

Jul 18, 2025 16:50 CST Updated 16:50

AstraZeneca

Biopharmaceutical Manufacturer

On July 18, the CDE website showed that AstraZenecaAZD9793 Approved for Clinical Use, Intended forGlypican 3（GPC3）Advanced or metastatic solid tumors with positive expression。Insight database shows that this product isThe world's first and currently onlyA GPC3/TCR/CD8 tri-specific antibody under research.

Screenshot source: Corporate official website

AZD9793 is a novel CD8-directed TCE,Containing two components that can bind to the surface of cancer cells in humansGPC3The Fab domain, a combination with humanTCR The VHH binding domain combined with a human T cell-expressedCD8 VHH binding domain for co-receptor engagement.Currently under development for the treatment ofGPC3 Positive Solid Tumors, includingHepatocellular Carcinoma (HCC)。

In January 2025, AstraZeneca launched a Phase I/II clinical study of the drug.（NCT06795022）, planning to enroll 304 participants in the United States, Japan, Hong Kong, China, and South Korea. In March 2025, the trial completed the enrollment of its first patient.

Screenshot source: Insight database

Scan the WeChat QR code, add the editor of the Antibody Circle, and those who meet the requirements can join the Antibody Circle WeChat group!

Please indicate: Name + Research Direction!

All reproduced articles in this official account are intended to convey more information, with the source and author clearly indicated. Media or individuals who do not wish to be reproduced can contact us (cbplib@163.com), and we will delete the content immediately. All articles represent the views of the author and do not represent the position of this website.